40 måneders behandling af nukleosid analog behandling forud for indkluderingen (gennemsnitlig 115 uger).
These heavily experienced patients demonstrated a significant improvement of the triple therapy group over the double therapy group for one year in both viral RNA and CD4+ cell counts.